Syndrome X and Endothelial Dysfunction

Syndrome X Clinical Trial

Status Terminated

Clinical Trial Summary

Cardiac syndrome X is characterized by angina, positve stress test, and patent coronary angiography, and its probable mechanism is microvascular dysfunction associated with endothelial dysfunction. We used brachial artery flow-mediated vasodilation to assess the endothelial function of the patients with syndrome X, coronary artery disease, and controls. Methods: We enrolled 28 patients with syndrome X, 11 healthy volunteers and 11 coronary artery disease patients. All subjects underwent a 2-step brachial artery flow-related vasodilation test: ultrasound artery diameter was measured at rest and after occlusion to assess endothelium-dependent vasodilation and after sublingual nitroglycerin to determine endothelium-independent condition. Serum endothelin-1 assay was performed for all participants. Results: The cardiac syndrome X patients had lower brachial artery dilation ratio (diameter after test/ diameter before test) than controls (1.10 +/- 0.09 versus 1.27 +/- 0.11, p=0.013), but the ratio is still higher than CAD patients (1.10 +/- 0.09 versus 1.02 +/- 0.07, p<0.001). After sublingual nitroglycerin, all 50 subjects had adequate vasodilation. Besides, normal controls have higher endothelin-1 level than the others.

We concluded that syndrome X patients have worse endothelial function than healthy control, but patients of CAD had even worse endothelium function than cardiac syndrome X patients.

Keywords: Cardiac syndrome X, coronary artery disease, endothelium-dependent vasodilation, endothelium-independent vasodilation, flow-mediated vasodilation, endothelin-1

Clinical Trial Description

Cardiac syndrome x (CSX), which is defined as the combination of typical chest pain, electrocardiography or nuclear medicine evidence suggesting myocardial ischemia, and patent coronary arteriogram, comprises approximately 10-30% of the patients undergoing coronary angiogram.1,2 However, since it was first introduced in 1973, the pathogenesis of CSX has remained an enigma.1, 2 Among all the hypothetic explanations of CSX, including abnormal pain perception and non-cardiogenic origin of pain, the coronary microvascular dysfunction (microvascular angina), which represents reduced microvascular dilatory response and increased resistence, has been consistently found in CSX patients. 2, 3 This microvascular angina is believed to bridge the gap between the ischemic evidence and the normal-looking of coronary tree of CSX, and seems attributed to the endothelium dysfunction (ED), another frequently reported abnormality in CSX.2.3 By definition, ED is characterized by the endothelium-dependent vasodilation (EDVD) impairment, which is believed to be caused by decreased release of NO activity and/or activity, while the endotheliumindependent vasodilation (EIVD) remains preserved. 2,3,4 Therefore, it is asserted that endothelium-dependent dilatation of the resistance coronary arteries is defective in patients with CSX, and such defects may contribute to the altered regulation of myocardial perfusion in these patients.5 On the other hand, ED play a pivotal role in the development, progression, and clinical manifestations of atherosclerosis, as well as in the development of ischemia and thrombosis in the late stages of the disease, by promoting coronary vasoconstriction and thrombosis.4 Instead of using invasively intravascular measuring method used for endothelial function assessment, Celermajer et al first introduced the non-invasive measurement of the flow-mediated vasodilation (FMD) of forearm brachial artery in the assessment of EDVD and EIVD.6 This method was reported to have good correlation to the invasively intravascular studies in coronary systems.4 In this study, we want to compare the difference of forearm FMD, which respond to specially programmed stimuli, in three patient groups: CSX, coronary artery disease (CAD), and normal volunteers. A two-staged stimulation strategy is utilized to assess the EDVD (with cuff occlusion) and EIVD (with sublingual nitroglycerin) consecutively. A baseline plasma endothelin-1 (ET-1) concentration is also checked for each patient enrolled. ;

Study Design

Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

• Syndrome X

• NCT number: NCT00190086
• Study type: Observational
• Source: Far Eastern Memorial Hospital
• Status: Terminated
• Phase: Phase 4
• Start date: January 2001
• Completion date: December 2001